Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
The Ministry of Health, Labor and Welfare (MHLW) issued a pharmaceutical safety information bulletin on March 30, calling on physicians to stick to the approved dosage and administration for GlaxoSmithKline K.K.’s (GSK) antiepileptic agent Lamictal (lamotrigine). GSK issued a flash…
To read the full story
Related Article
- GSK Ordered to Issue Blue Letter on Lamictal
February 5, 2015
REGULATORY
- MOF Panel Pushes for Full Drug Price Revision in FY2027: Budget Proposal
November 20, 2026
- Mumps Shots Gain Strong Backing as Japan Weighs FY2027 NIP Priorities
November 20, 2026
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026





